NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
May 10, 2022 16:01 ET
|
NexImmune, Inc.
A JDRF funded grant will be used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md.,...
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
May 10, 2022 07:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center
April 26, 2022 07:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
April 14, 2022 16:01 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., April 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
March 17, 2022 07:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel...
NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center
March 14, 2022 07:30 ET
|
NexImmune, Inc.
GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune to Present at the Barclays 2022 Global Healthcare Conference
March 10, 2022 16:26 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
March 09, 2022 16:33 ET
|
NexImmune, Inc.
Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H22Investigational New Drug (IND) submission for NEXI-003, the Company’s first product for...
NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors
February 17, 2022 16:15 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets
February 01, 2022 07:00 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...